DRP Journal

Discover Research Profit

Finance 

Enzolytics Inc (OTCMKTS:ENZC) Stock Continues To Move Higher

Ian Leigh , , , ,

Drug development biotech company Enzolytics Inc (OTCMKTS:ENZC) had made a significant new announcement back on May 5. It announced that Virogenetics, its fully owned subsidiary unit, was going to conduct a pilot clinical trial test for the Bulgarian National Center for Endocrinology, which is owned by the Bulgarian government.

Trading Data

On Monday, ENZC stock soared 28.32% to $0.1101 with more than 28.28 million shares, compared to volume of 6.99 million shares. The stock moved within a range of $0.0890 – 0.1120 after opening trade at $0.0904.

Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line

The trial test is going to be focussed on gauging the effectiveness of the ITV-1 immunotherapy on diabetes. The subsidiary is looking to transform to industrial production at the VetProm-Dancon plant in Bulgaria from laboratory production. To that end, Virogenetics had also bought a flow machine for the purpose of sterile filling of the treatment into single vials.

At the facility, Virogenetics had managed to complete the initial order for the immunotherapy treatment, which would be distributed to some of the participating hospitals from Africa. The order is scheduled for delivery on May 10, 2023. The treatments are supposed to administered through intramuscular injections two times a week over the course of an eight week period.

However, there would be a single week of breaks between each cycle. By late fall of 2023, the results from the treatment are going to be made available.

Ian Leigh

Ian Leigh is a specialist in analyzing stocks, SEC and OTC filings, and financials of public and privately-held companies. He has played a significant role in M&A activity, consulting with publicly-held firms on acquisitions and divestitures. He also consults on valuations and branding. He lectures at major universities and teaches at specialty financial schools.